Egetis Therapeutics AB (publ) Profit Margin

Egetis Therapeutics AB (publ) (EGTX.ST) currently reports a profit margin of -613.46% as of June 2026. That compares with -711.39% in the prior-year period — up 13.8% year over year. That is below the Healthcare sector average of 9.48%. Use the charts on this page to explore Egetis Therapeutics AB (publ)'s profit margin history and peer comparisons.

Egetis Therapeutics AB (publ)'s profit margin increased from -711.39% to -613.46% — a 13.8% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Egetis Therapeutics AB (publ)'s profit margin of -613.46% is lower than the Healthcare sector average of 9.48%. That is roughly 6570.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Egetis Therapeutics AB (publ)'s current -613.46% should be judged against Healthcare norms (sector average: 9.48%) and against EGTX.ST's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -613.46%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 9.48%. From there, open related valuation or income-statement pages for Egetis Therapeutics AB (publ), and consider following EGTX.ST for alerts when major investors trade the stock.